First Line Hepato Cellular Carcinoma (HCC)

NCT00858871 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1714

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepato Cellular Carcinoma (HCC)

Interventions

DRUG: Brivanib
DRUG: Placebo
DRUG: Sorafenib
DRUG: Placebo

Sponsor

Bristol-Myers Squibb